

1 Clinical and Virological Features of patients hospitalized with different types
2 of COVID-19 vaccination in Mexico City

3

4 Alejandra Hernández-Terán¹, Pamela GarciaDiego², Marco Villanueva-Reza², Celia Boukadida³, Blanca Taboada⁴,
5 Eduardo Porras², Victor Ahumada-Topete², Kathia Tapia Diaz³, Margarita Matias-Florentino³, Marissa Pérez-García³,
6 Santiago Ávila-Rios³, Fidencio Mejía-Nepomuceno¹, Ricardo Serna-Muñoz¹, Fortunato Juárez-Hernández⁵, Maria
7 Eugenia Jiménez-Corona⁶, Eduardo Becerril-Vargas⁷, Omar Barreto⁸, Jose Arturo, Martínez-Orozco⁷, Rogelio Pérez-
8 Padilla¹, Carlos F. Arias⁴, Joel Armando Vázquez-Pérez¹.

9 [^]These authors contributed equally to this work.

10 ¹Departamento de Investigación en Tabaquismo y EPOC. Instituto Nacional de Enfermedades Respiratorias Ismael Cosío
11 Villegas, INER, Ciudad de Mexico.

12 ²Departamento de Unidad de Epidemiología Hospitalaria e Infectología. Instituto Nacional de Enfermedades Respiratorias
13 Ismael Cosío Villegas, INER, Ciudad de Mexico.

14 ³Centro de Investigación en Enfermedades Infecciosas, CIENI,
15 Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Ciudad de Mexico.

16 ⁴Departamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional
17 Autónoma de México, Ciudad de Mexico.

18 ⁵Departamento de Imagenología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Ciudad
19 de Mexico.

20 ⁶Departamento de Epidemiología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico.

21 ⁷Laboratorio de Microbiología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Ciudad de
22 Mexico.

23 ⁸Coordinación de Atención Médica, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER,
24 Ciudad de Mexico.

25 **Corresponding authors:** Carlos F Arias, Joel Armando Vazquez-Perez

26 E-mail: carlos.arias@ibt.unam.mx / joevazpe@gmail.com

27

28

29

30 **ABSTRACT**

31 Coronavirus disease 2019 (COVID-19) vaccines are very effective at protecting against severe
32 disease and death. However, the impact of the vaccine used, viral variants, and host factors on
33 disease severity remain poorly understood. Here we compared COVID-19 clinical presentations and
34 outcomes in vaccinated and unvaccinated patients in Mexico City. From March to September 2021,
35 clinical and demographic characteristics were obtained from 1,014 individuals with a documented
36 SARS-CoV-2 infection, and viral variants were identified in a subset of 386 patients. We compared
37 unvaccinated, partially vaccinated, and fully vaccinated patients, stratifying by age groups. We
38 fitted multivariate statistical models to evaluate the impact of vaccination status, SARS-CoV-2
39 lineages, vaccine types, and clinical parameters. Most hospitalized patients were unvaccinated. In
40 patients over 61 years old, mortality was significantly higher in unvaccinated compared to fully
41 vaccinated individuals. In patients aged 31 to 60 years, vaccinated patients were more likely to be
42 outpatients (46%) than unvaccinated individuals (6.1%). We found immune disease and age above
43 61 years old as risk factors. While fully vaccination was found as the most protective factor against
44 in-hospital death. This study suggests that vaccination is essential to reduce mortality in a comorbid
45 population such as that of Mexico.

46

47 **KEYWORDS:** COVID-19, vaccination, SARS-CoV-2 lineages, COVID-19 severity.

48

49

50

51

52

53

54

55 INTRODUCTION

56 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in
57 Wuhan, China, in December 2019 [1]; since then, more than 500 million people have been
58 infected, and over six million have died worldwide [2]. SARS-CoV-2 has evolved and
59 several mutations throughout the genome have been detected worldwide [3]. Genomic
60 mutations are anticipated events during virus replication, and although most mutations are
61 expected to be neutral some can confer a fitness advantage and be fixed in the viral genome
62 [4,5]. The accumulation of mutations over time generates new SARS-CoV-2 variants [6].
63 The World Health Organization (WHO) has classified them as variants of concern (VOC),
64 variants of interest (VOI), and variants under monitoring (VUM) (WHO, tracking SARS-
65 CoV-2 variants). VOC are SARS-CoV-2 variants with increased transmissibility, virulence,
66 or decreased effectiveness of vaccines, therapeutics, diagnostics, or public health and social
67 measures [6].
68 As in other countries, in Mexico, several variants classified as VOC, VOI, and VUM have
69 been detected, particularly Delta, Alpha, Gamma, Mu [7], and more recently Omicron [8].
70 Moreover, B.1.1.519 was detected as the predominant lineage in Mexico during late 2020
71 and the first months of 2021 [9]. The B.1.1.519 lineage was dominant during the second
72 COVID-19 wave in Mexico and may have been associated with an increased risk of severe
73 and fatal outcomes [10].
74 In Mexico, vaccination against COVID-19 began in December 2020 with the health
75 personnel and people older than 60 years old, followed by people over 50. Until September
76 30, 2021, 101,190,484 doses have been applied with a variety of platforms; of which
77 43,431,200 doses were of Oxford-AstraZeneca (ChAdOx1 nCov-19 adenoviral vector),
78 33,022,275 of Pfizer BioNTech (RNA platform, mRNA-BNT162b2), 20,000,000 of

79 SinoVac (inactivated virus), 9,900,000 of Sputnik V (Gam-COVID-Vac), 8,149,930 of
80 CanSino (Convidecia or AD5-nCOV); 3,500,000 of Moderna (mRNA-1273), and
81 1,350,000 of Janssen (AD26.coV2.s). By the end of September 2021, almost 50% of the
82 population over 18 years old had received at least one dose of vaccine [11].
83 Importantly, COVID-19 vaccines have been shown to be effective at preventing severe
84 disease and death even in patients with comorbidities [12]. As a result, fully vaccinated
85 persons are less likely to experience severe disease or death than unvaccinated persons with
86 the same medical conditions [13]. Nonetheless, vaccines are less effective at protecting
87 from SARS-CoV-2 infections, and this partial protection seems to wane after a few months,
88 leading to infections in vaccinated individuals (breakthrough infections) [14]. Furthermore,
89 one of the most critical factors behind the changing vaccine effectiveness is the viral
90 variability and the mutations that affect the recognition of neutralizing antibodies elicited
91 by vaccination or previous infections [15,16]. These mutations are located mainly in the
92 Receptor Binding Domain (RBD) of Spike protein [17].
93 Understanding the impact of vaccination, viral variants, and host factors on disease severity
94 is critical to guide COVID-19 vaccination campaigns and protective measures. Here, we
95 analyzed the main risk factors for severe COVID-19, comparing the outcomes and clinical
96 presentation of vaccinated and unvaccinated patients, and analyzing the effects of both
97 SARS-CoV-2 lineages and vaccine types in a tertiary hospital in Mexico City from March
98 to September 2021.

99

100

101

102

103 **MATERIAL AND METHODS**

104 **Study participants and clinical data**

105 We analyzed 1014 patients with SARS-CoV-2 infection who received medical attention
106 from March to September 2021 at the Instituto Nacional de Enfermedades Respiratorias
107 (INER), belonging to the Ministry of Health of Mexico. INER is a reference hospital for
108 respiratory diseases that primarily provide services for uninsured individuals and was
109 designated as a hospital exclusive for COVID-19 in March 2020, offering between 150-200
110 beds for the attention of critically ill patients.

111 For all patients, demographic data, clinical symptoms, laboratory, radiology data, and
112 outcome-related information were obtained from electronic medical records. Clinical
113 management was performed according to the standards of care and attending physicians.
114 Follow-up went from the time of admission for up to 28 days. This study was reviewed and
115 approved by the Science, Biosecurity, and Bioethics Committee of the Instituto Nacional de
116 Enfermedades Respiratorias (B-10-20). In addition, the Institution requested informed
117 consent for the recovery, storage, and use of biological remnants for research purposes.

118

119 **SARS-CoV-2 diagnostics**

120 Oropharyngeal and/or nasopharyngeal swabs were collected, and the diagnosis was made
121 using validated RT-qPCR protocols for SARS-CoV-2 RNA detection, approved by the
122 World Health Organization (WHO).

123

124 **RNA extraction and sequencing**

125 *Complete genome sequencing*

126 Viral nucleic acid extraction was performed using a MagNa Pure L.C. 2-0 system (Roche,
127 Indianapolis, OH, USA) or QIAamp viral RNA Minikit (Qiagen, Hilden Germany).
128 Libraries for whole-genome sequencing of SARS-CoV-2 were generated using the protocol
129 developed by the ARTIC Network (<https://artic.network/2-protocols.html>) or a long-
130 amplicon-based method [18]. Libraries were sequenced on a MiSeq sequencing platform
131 using a 2x150-cycle or a NextSeq 500 platform using 2x150-cycle mid-output kits to obtain
132 paired-end reads (Illumina, San Diego, CA, USA). The DRAGEN COVIDSeq Test
133 Pipeline on BaseSpace Sequence Hub performed the analysis, mapping, and consensus.

134

135 *Spike partial sequencing*

136 Partial sequencing of the Spike segment was performed by Sanger sequencing in samples
137 with incomplete genome or samples with cycle threshold (Ct) values above 28. Briefly, 956
138 bp amplicons (944-1900 nucleotide sequence, 315-633 aa) were obtained using specific
139 primers for SARS-CoV-2:

140 SF3 CTTCTAACTTTAGAGTCCAACC and SR4 GCCAAGTAGGAGTAAGTTGAT.

141 The amplicons were sequenced in both directions with the same primers. Sequencing
142 reactions were performed with BigDye Terminator v3.1 (Life Technologies, Carlsbad, CA)
143 as instructed by the manufacturer. Sequences were obtained by capillary electrophoresis
144 using an ABI Prism 3500 Genetic Analyzer (Life Technologies) and were assembled using
145 MEGA 10.0 [19]. The sequences mentioned above can be found at GenBank (accession
146 numbers: ON158371-ON158443).

147

148

149

150 **Phylogenetic analysis**

151 To perform a phylogenetic analysis, we analyzed only samples with complete genomes of
152 hospitalized and ambulatory patients from our cohort (N= 311). In addition, for the
153 genomic surveillance, 219 complete Mexican genomes available in the GISAID platform,
154 including 140 sequences of INER from May 2020 to November 2020, 42 and 37 sequences
155 of different States of Mexico from March 2020 to November 2020, and March 2021 to
156 September 2021 respectively were used. Also, we included 10 USA sequences from
157 January 2020 to November 2021 and one Wuhan 2019 sequence for reference. To construct
158 the analysis, we selected only the Spike sequences of these 541 sequences. Sequence
159 alignments were created with MAFFT V7 [20] and edited with MEGA 10.0. A maximum-
160 likelihood tree was constructed for the whole Spike sequence using MEGA 10.0. The
161 General Time-Reversible (GTR) model was selected with 5-parameter gamma-distributed
162 rates and 1,000 bootstrap replicates. Edition of the trees was made using FigTree [21].

163

164 **Statistical analyses**

165 To evaluate the impact on clinical outcomes, we divided our cohort into three groups: 1)
166 unvaccinated: defined as those patients who had never received a SARS-CoV-2 vaccine; 2)
167 partially vaccinated: defined as those patients who had not yet completed the standard
168 vaccination schedule (depending on the vaccine) or had received the last dose less than 14
169 days before symptom onset; and 3) fully vaccinated: defined for those patients who had
170 already completed the vaccination schedule and with more than 14 days after the last dose.
171 As advanced age is a significant driver of severe COVID-19 [22]; we categorized patients
172 into three groups: <30 years old, 31-60 years old, and > 61 years old. In addition, the
173 severity of the disease was categorized according to the NIH COVID-19 treatment

174 guidelines [23] into four groups: 1) Mild illness: individuals who have any of the various
175 signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache,
176 muscle pain, nausea, vomiting, diarrhea, loss of taste, and smell) but who do not have
177 shortness of breath, dyspnea, or abnormal chest imaging, 2) Moderate illness: individuals
178 who show evidence of lower respiratory disease during clinical assessment or imaging and
179 who have an oxygen saturation (SpO_2) $>94\%$ on room air at sea level, 3) Severe illness:
180 individuals who have $SpO_2 <94\%$ on room air at sea level, a ratio of arterial partial pressure
181 of oxygen to fraction of inspired oxygen (PaO_2/FiO_2) <300 mmHg, a respiratory rate >30
182 breaths/min, or lung infiltrates in $>50\%$ of the lung fields, and 4) Critical illness:
183 individuals who have respiratory failure, septic shock, or multiple organ dysfunction.
184 All statistical analyses were performed using R v4.0.2 in RStudio v1.3.1 [24] and the
185 packages ggplot2 (v3.3.3) [25], stats (v3.6.2) [24], survival (v3.2.13) [26], and survminer
186 (v0.4.9) [27]. We used stacked bar plots, density plots, pie charts, or heatmaps constructed
187 in the ggplot2 package to represent data proportion. For numerical data representation, we
188 used boxplots constructed in the ggplot2 package. For all cases, categorical variables were
189 statistically compared using Chi-square or Fisher's exact test and continuous variables using
190 Wilcoxon rank-sum test in R base.
191 To predict the clinical outcome (deceased vs. recovered) we constructed Generalized Linear
192 Models (GLM) using a Binomial family with a *logit* link in R base. We fitted one model as
193 a function of vaccination status and another model as a function of clinical parameters.
194 Both models were adjusted by comorbidities, age, and sex. Odds ratios and 95% CI for all
195 selected variables were calculated and plotted in the final model. Finally, to detect variables
196 that significantly affect survival probability, we calculated Kaplan-Meier curves coupled
197 with the Cox proportional hazard models to determine factors affecting survival, using the

198 survival package and plotted with the survminer package. We used the hospitalization
199 length in days as a time variable for all curves, the outcome (deceased or recovered)
200 standardized at 28 days as a dependent variable, and the tested variables as exposure.
201 Finally, for both the GLM and the Kaplan-Meier curves, we categorized the numerical
202 variables (e.g., age, D dimer.) into three groups according to the data distribution: 1) all
203 values under the 25th percentile, 2) values between the 25th and 75th percentiles, and 3)
204 values above the 75th percentile.

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222 **RESULTS**

223 **Clinical and demographic characteristics of the cohort**

224 A total of 1014 patients admitted to INER from March to September 2021 positive for
225 SARS-CoV-2 infection were included. 124 (12%) were outpatients, and 890 (88%) were
226 hospitalized due to respiratory failure. 48 patients in the cohort had incomplete information;
227 thus, only 111 out of 124 outpatients and 855 out of 890 hospitalized patients had their
228 clinical and demographic data analyzed (Table 1).

229

230 For outpatients, the median age was 39.5 years (IQR: 30-52), 47.7% were female, and 64%
231 of the patients were either partially (28.8%) or fully (36%) vaccinated. The most frequently
232 administered vaccine in fully vaccinated patients was Pfizer (70%), followed by Sinovac
233 (12%) and AstraZeneca (10%). The most commonly administered vaccines in partially
234 vaccinated patients were AstraZeneca (40.6%) and Pfizer (37%). 13.5% of the patients had
235 at least one comorbidity, obesity being the most common (14.4%), particularly in
236 unvaccinated (12.8%) and partially vaccinated (21.8%). For fully vaccinated outpatients,
237 the most common comorbidity was hypertension (12.5%). Only eight patients received
238 dexamethasone (7%) as in-hospital treatment, with the highest prevalence in the
239 unvaccinated group (12.8%). Among the outpatients, unvaccinated patients reported fever
240 (48.7%, Chi-square test, $p = 0.01$) and headache (33.3%, Chi-square test, $p = 0.01$) more
241 frequently than vaccinated individuals. While partially vaccinated patients reported a higher
242 prevalence of arthralgias (31.2%, Chi-square test, $p = 0.002$). Diarrhea was less frequently
243 reported in partially vaccinated patients (3.1%, Chi-square test, $p = 0.01$). The rest of the
244 symptoms were equally reported.

245

Table 1. Demographics of the cohort.

	Outpatients (N=111)				Hospitalized (N=855)			
	Unvaccinated (N=39) [35.1%]	Partially vaccinated (N=32) [28.8%]	Fully vaccinated (N= 40) [36%]	P	Unvaccinated (N=572) [66.9%]	Partially vaccinated (N=178) [20.8%]	Fully vaccinated (N=105) [12.2%]	P
Age								
<30, n (%)	13 (33.3%)	4 (12.5%)	14 (35%)	0.03	54 (9.4%)	1 (0.5%)	0	<0.001
31-60, n (%)	25 (64.1%)	22 (68.7%)	18 (45%)	0.04	382(66.7%)	132 (74.1%)	21 (20%)	<0.001
=/>60, n (%)	1 (2.50%)	6 (18.7%)	8 (20%)	0.03	135(23.6%)	45 (25.2%)	82 (78%)	<0.001
NA	0	0	0		1	0	2	
Gender								
Female, n (%)	17 (43.5%)	20 (62.5%)	16 (40%)	ns	200(34.9%)	65 (36.5%)	52 (49.5%)	0.02
NA	0	0	0		0	0	0	
Vaccine type								
Total of vaccinated patients		32 (100%)	40 (100%)			179 (100%)	104 (100%)	
Pfizer, n (%)	na	12(37%)	28 (70%)	0.01	na	34 (19%)	14 (13.3%)	ns
AztraZeneca, n (%)	na	13(40.6%)	4 (10%)	0.02	na	69 (38.7%)	15 (14.2%)	<0.001
SinoVac, n (%)	na	3 (9.3%)	5 (12%)	ns	na	18 (10.1%)	35 (33.3%)	<0.001
Sputnik, n (%)	na	2 (6.2%)	2 (5%)	ns	na	51 (28.6%)	21 (20%)	ns
Cansino, n (%)	na	0	1 (2.5%)	na	na	na	18 (17.1%)	na
J&J, n (%)	na	0	0	na	na	1 (0.56%)	0	ns
Moderna, n (%)	na	0	0	na	na	0	1 (0.95%)	ns
NA	na	2	0		na	5	1	
Comorbidities								
Diabetes, n (%)	2 (5.1%)	4 (12.5%)	1 (2.5%)	ns	115 (20.1%)	44 (24.7%)	42 (40%)	<0.001
Hypertension, n (%)	5 (12.8%)	4 (12.5%)	5 (12.5%)	ns	147 (25.6%)	45 (25.2%)	53 (53.3%)	<0.001
Obesity, n (%)	5 (12.8%)	7 (21.8%)	4 (10%)	ns	255 (44.5%)	82 (46%)	47 (44.7%)	ns
Smoking, n (%)	2(5.1%)	1 (3.1%)	2 (5%)	ns	177 (30.9%)	57 (32%)	25 (23.8%)	ns
COPD, n (%)	0	0	2 (5%)	na	12 (2%)	2 (1.1%)	4 (3.8%)	ns
Immune disease, n (%)	0	0	2 (5%)	na	12 (2%)	1 (0.5%)	3 (2.8%)	ns
NA	89	85	105		33	13	10	
Number of comorbidities								
None, n (%)	22 (56.4%)	13 (40.6%)	25 (62.1%)	0.05	97 (16.9%)	34 (19.1%)	10 (9.5%)	0.05
1, n (%)	9 (23.07%)	2 (6.2%)	4 (10%)	ns	217 (37.9%)	58 (32.5%)	21 (20%)	<0.001
2, n (%)	2 (5.1%)	1 (3.1%)	4 (10%)	ns	170 (29.7%)	55 (30.8%)	35 (33.3%)	ns
=/> 3, n (%)	1 (2.5%)	3 (9.3%)	2 (5%)	ns	87 (15.2%)	31 (17.4%)	39 (37.1%)	<0.001
NA	5	13	5		1	0	0	
In-hospital treatment								
Dexamethasone, n (%)	5 (12.8%)	2 (6.2%)	1 (2.5%)	ns	554 (96.8%)	169 (94.9%)	98 (93.3%)	ns
Remdesivir./Baricitinib, n (%)	0	0	0	na	11 (1.9%)	3 (1.6%)	3 (2.8%)	0.02
Remdesivir/Dexamethasone,n(%)	0	0	0	na	4 (0.6%)	0	1 (0.95%)	ns
Dexamethasone./Baricitinib, n (%)	0	0	0	na	1 (0.1%)	2 (1.1%)	0	ns
NA	5	13	6		0	0	2	
Previous steroid								
Dexamethasone, n (%)	0	0	0	na	202 (35.3%)	66 (37%)	40 (38%)	ns
Prednisone, n (%)	0	0	0	na	28 (4.8%)	0	5 (4.7%)	0.001
Betamethasone, n (%)	0	0	0	na	12 (2%)	7 (3.9%)	2 (1.9%)	ns
Dexamethasone./Prednisone, n (%)	0	0	0	na	6 (1.04%)	2 (1.1%)	0	ns
Dexamethasone./Betamethasone, n (%)	0	0	0	na	5 (0.87%)	4 (2.2%)	0	ns
NA	5	13	6		0	0	2	
Symptoms								
Fever, n (%)	19 (48.7%)	10 (31.2%)	12 (30%)	0.01	409 (71.5%)	134 (75.2%)	57 (54.2%)	<0.001
Cough, n (%)	19 (48.7%)	19 (59.3%)	15 (37.5%)	ns	333 (58.2%)	107 (60.1%)	68 (64.7%)	ns
Diarrhea, n (%)	4 (10.2%)	1 (3.1%)	4 (10%)	0.01	61 (10.6%)	17 (9.5%)	6 (5.7%)	ns
Myalgias, n (%)	9 (23%)	7 (21.8%)	11 (27.5%)	ns	382 (66.7%)	111 (62.3%)	65 (61.9%)	ns
Arthralgias, n (%)	10 (25.6%)	10 (31.2%)	8 (20%)	0.002	163 (28.4%)	47 (26.4%)	24 (22.8%)	ns
Nasal congestion, n (%)	0	0	2 (5%)	na	51 (8.9%)	21 (11.7%)	11 (10.4%)	ns
Pharyngodynia, n (%)	7 (17.9%)	7 (21.8%)	11 (27.5%)	ns	140 (24.4%)	57 (32%)	29 (27.6%)	0.05
Anosmia, n (%)	2 (5.1%)	3 (9.3%)	2 (5%)	ns	43 (7.5%)	14 (7.8%)	3 (2.8%)	ns
Headache, n (%)	13 (33.3%)	7 (21.8%)	13 (32.5%)	<0.001	190 (33.2)	60 (33.7%)	33 (31.4%)	ns
NA	5	20	14		0	0	18	

247 **COPD:** Chronic obstructive pulmonary disease

248 **NA:** Data not available

249 P values were obtained from Chi-square or Fisher exact test.

250 **ns=** non-significant, **na=** not available comparison.

251

252

253

254

255

256 For hospitalized patients, the median age was 52 (IQR: 41-64), and 37% were female. Most
257 patients were unvaccinated (66.9%), while 20.8% were partially vaccinated and 12.2%
258 were fully vaccinated. For fully vaccinated patients, the most frequently administered
259 vaccines were Sinovac (33.3%), Sputnik (20%), and Cansino (17.1%), while for partially
260 vaccinated patients, AstraZeneca (38.7%), Sputnik (28.6%), and Pfizer (19%) were the
261 most frequently administered. 34.6% had at least one comorbidity. Obesity was the most
262 frequent comorbidity in the three compared groups (unvaccinated: 44.5%, partially
263 vaccinated: 46%, and fully vaccinated: 44.7%). In general, fully vaccinated patients were
264 significantly older (median: 70, Chi-square test $p < 0.001$) and showed higher prevalence of
265 diabetes (40%, Chi-square test $p < 0.001$), hypertension (53.3%, Chi-square test $p < 0.001$),
266 and three or more comorbidities (37.1%, Chi-square test $p < 0.001$). Above 90% of
267 hospitalized patients (regardless of the vaccination status) received in-hospital treatment,
268 being dexamethasone the most administered (unvaccinated: 96.8%, partially vaccinated:
269 94.9%, and fully vaccinated: 93.3%). Fever and pharyngodinia were more frequently
270 reported by partially vaccinated patients (75.2% and 32%, respectively, Chi-square test, $p <$
271 0.05). The rest of the symptoms were equally reported.

272 Furthermore, we found no differences in the radiological patterns between study groups.
273 Most of the patients presented a crazy-paving pattern regardless of the vaccination status
274 (unvaccinated: 57.6%, partially vaccinated: 67.4%, fully vaccinated: 68.5%), while the least
275 showed pattern was consolidation (unvaccinated: 6.2%, partially vaccinated: 3.3%, fully
276 vaccinated: 4.8%).

277

278

279 **Impact of vaccination status and age on the severity and clinical parameters of**
280 **COVID-19 patients**

281 We compared the distribution of COVID-19 severity, severity indexes, O₂ requirement, and
282 laboratory parameters among patients with different vaccination status and age (Fig. 1-2).


283 Overall, due to the timing of the vaccination campaign in Mexico, most of the vaccinated
284 patients were received from June to August, while unvaccinated patients arrived at the
285 hospital in equal proportion during the sampling months (Suppl. Fig. S1).

286 In general, we found that a large proportion of patients were classified either as severe or
287 critical, regardless of age and vaccination status (Fig. 1A). Nonetheless, the highest
288 proportion of patients with mild disease was found in fully vaccinated patients under 30
289 years old (Suppl. Table S1, Chi-square test $p < 0.001$), while the highest proportion of
290 critical patients were unvaccinated older than 61 years old (Suppl. Table S1, Chi-square test
291 $p < 0.001$). It is essential to highlight that for older patients (>61 years) the vaccination
292 status seems to be associated with less disease severity, reducing the number of critical
293 patients (Suppl. Table S1, unvaccinated against vaccinated patients; Chi-square test $p =$
294 0.001) and slightly increasing the number of patients with mild disease in the vaccinated
295 groups (Suppl. Table S1, Chi-square test $p < 0.002$). Furthermore, we do not find statistical
296 differences in the most commonly used ICU scales (Fig. 1B) (SOFA and APACHE II).
297 Nonetheless, we detected that, although most of the patients were subjected to mechanical
298 ventilation, the highest proportion of intubated patients was in the unvaccinated group (Fig.
299 1C).

300

301

302



303

304 **Figure 1. Impact of vaccination status and age in severity and clinical parameters in COVID-19**

305 **patients A.** Barplot shown the proportion of COVID-19 severity classification among unvaccinated,

306 partially vaccinated, and fully vaccinated patients between age groups. Statistically significant


307 differences are available in Supplementary Table S1. **B.** Boxplot of Sequential Organ Failure

308 Assessment (SOFA) score and Acute Physiology and Chronic Health Evaluation II (APACHE) among

309 patients with different vaccination status and age. **C.** Heatmap of the O₂ requirement among patients

310 with different vaccination status. HFNC: High Flow Nasal Cannula.

311 Finally, we also investigated whether patients with different vaccination status and age
312 differ in laboratory parameters (Fig. 2). The most remarkable differences were found in the
313 unvaccinated group, particularly when comparing patients <30 years with >61 years. For
314 instance, we found that, regardless of the vaccination status, patients older than 61 years
315 exhibited the highest values for blood urea nitrogen (BUN), urea, creatinine (only
316 statistically significant in unvaccinated patients), and D-dimer. In addition, patients in the
317 age groups of <30 and 31-60 showed the highest values for lymphocytes, hematocrit, and
318 albumin (only statistically significant in unvaccinated patients).
319




320
321 **Figure 2. Laboratory parameters that significantly vary among vaccination status and age group.** We
322 used logarithmic distribution in the lymphocytes and D dimer parameters for visualization purposes.
323 Statistically significant differences are given by Wilcoxon rank-sum test. Units: Lymphocytes ($10^3/\text{mm}^3$),
324 Blood Urea Nitrogen (BUN) (mg/dL), Glucose (mg/dL), Albumin (g/dL), Hematocrit (%), Urea (mg/dL),
325 Creatinine (mg/dL), D dimer (mg/dL).

326 **Impact of different vaccines on the severity of the disease**

327 By September 2021, more than 100 million doses of seven different vaccines were
328 administered in the Mexican territory, with AstraZeneca (42.9%), Pfizer (32.6%), Sinovac
329 (19.7%), and Sputnik (9.7%) being the most common (Fig. 3A). This heterogeneity of
330 vaccine strategies is also found in our cohort, where 142 patients were fully vaccinated with
331 five different vaccines being Pfizer (29.5%), Sinovac (28.1%), Sputnik (16.1%),
332 AstraZeneca (13.3%), and Cansino (11.9%) the most administered (Fig. 3B). This allowed
333 us to analyze the effect of the different vaccines on the severity of the disease. To isolate
334 the age effect (Suppl. Figure S2), we kept only fully vaccinated patients above 61 years old
335 (N=88) and tested for differences in the severity of the disease, O₂ requirement, and
336 severity indexes (Fig. 3C-E). Regarding COVID-19 classification, we found that all
337 patients vaccinated with AstraZeneca (N=12) or Cansino (N=7) coursed a severe or critical
338 disease without patients in the mild disease group (Fig. 3C), although this may be due to
339 small sample sizes. Also, we found the highest proportion of patients with mild disease in
340 the Pfizer group (Fig. 3C and Suppl. Table S2) (16.6%, Chi-square test $p = 0.02$).
341 Furthermore, patients vaccinated with AstraZeneca, Sinovac, and Sputnik had mostly a
342 critical disease (66%, 51.4%, and 59%, respectively). Regarding O₂ requirement, although
343 most of the patients were subjected to mechanical ventilation, AstraZeneca was the group
344 with the highest proportion (66%). Pfizer was the group with the highest proportion of
345 patients with a nasal cannula (16.6%, Chi-square test $p = 0.01$), and the Cansino group had
346 the highest proportion of high flow nasal cannula (HFNC) (42.8%, Chi-square test $p =$
347 0.01). Finally, we found that the Sinovac group had significantly higher values for SOFA
348 (Fig.3E) compared to Pfizer (Wilcoxon rank-sum test, $p = 0.01$) and AstraZeneca

349 (Wilcoxon rank-sum test, $p = 0.02$). We did not find statistically significant differences in
 350 the APACHE II severity index.



351

352 **Figure 3. Distribution of vaccine strategies and their impact on disease severity in fully vaccinated**

353 **patients.** **A.** Piechart of the proportion of the vaccines applied at the national level. **B.** Piechart of the

354 proportion of the different vaccines applied at the INER. **C.** Barplot shown the proportion of COVID-19

355 classification in patients with different vaccines. **D.** Barplot depicting the proportion of O₂ requirement in

356 patients with different vaccines. **E.** Boxplot of Sequential Organ Failure Assessment (SOFA) score and Acute

357 Physiology and Chronic Health Evaluation II (APACHE) among patients with different vaccines. Statistically

358 significant differences are available in Supplementary Table S2-3. In C-E panels only patients >61 years old

359 were included.

360 **Clinical factors affecting COVID-19 clinical outcome**

361 Of the hospitalized patients, 77.1% were discharged fully recovered, while 21.2% died due
 362 to complications (Table 2), with the highest proportion of deceased patients in the
 363 unvaccinated group (70.8%). Regarding severity indexes, fully vaccinated patients had the
 364 highest median of APACHE II (median: 11, Wilcoxon rank-sum test, $p < 0.001$). Most of
 365 the patients were subjected to supplemental oxygen, with mechanical ventilation
 366 (unvaccinated: 65.5%, partially vaccinated: 58.9%, fully vaccinated: 58%), HFNC
 367 (unvaccinated: 23.6%, partially vaccinated: 28.4%, fully vaccinated: 26.6%), and nasal
 368 cannula (unvaccinated: 9.4%, partially vaccinated: 10.6%, fully vaccinated: 11.4%) being
 369 the most common.

370

371 **Table 2. Outcome, severity indexes, and O₂ requirement among hospitalized patients**
 372 **with different vaccination status.**

	Hospitalized (N=855)			P value
	Unvaccinated (N=572) [66.9%]	Partially vaccinated (N=178) [20.8%]	Fully vaccinated (N=105) [12.2%]	
Outcome				
Recovered, n (%)	433 (71.6%)	139 (78%)	88 (83.8%)	0.05
Deceased, n (%)	129 (22.5%)	37 (20.7%)	16 (15.2%)	<i>ns</i>
NA	10	2	1	
Severity indexes				
APACHE II, med(IQR)	8.5 (6-11)	9 (6.2-11)	11 (9-14)	<0.001
SOFA, med(IQR)	3 (3-4)	3 (3-4)	4 (3-4)	<i>ns</i>
GLASGOW, med(IQR)	15 (15-15)	15 (15-15)	15 (15-15)	<i>ns</i>
O₂ requirement				
Nasal cannula, n (%)	54 (9.4%)	19 (10.6%)	12 (11.4%)	<i>ns</i>
HFNC, n (%)	135 (23.6%)	50 (28%)	28 (26.6%)	<i>ns</i>
Mechanical ventilation, n (%)	375 (65.5%)	105 (58.9%)	61 (58%)	<i>ns</i>
Reservoir oxygen mask, n (%)	7 (1.2%)	3 (1.6%)	1 (0.9%)	<i>ns</i>
Non-invasive mechanical ventilation, n (%)	1 (0.1%)	1 (0.5%)	1 (0.9%)	<i>ns</i>
NA	0	0	2	

373 **NA:** Data not available

374 P values were obtained from Chi-square or Fisher exact test.


375 *ns*= non-significant, *na*= not available comparison.

376

377

378

379 Moreover, we applied multivariate statistical approaches to determine the factors that could
 380 explain mortality in COVID-19 patients. From the two fitted Generalized Linear Model
 381 (GLM) (Fig. 4A), we found that the presence of immune disease (OR: 3.12, 95% CI: 1.09-
 382 8.34, $p = 0.02$), age above 61 years old (OR: 3.51, 95% CI: 2.3-5.2, $p = 5.9e-10$), platelets
 383 count under $175 \times 10^9/l$ (OR: 1.49, 95% CI: 0.98-2.2, $p = 0.05$), lactate dehydrogenase
 384 (LDH) > 600 u/L (OR: 1.89, 95% CI: 1.2-2.7, $p = 0.001$), and D dimer > 1.8 ug/mL (OR:
 385 1.45, 95% CI: 0.98-2.1, $p = 0.05$) were factors associated with higher probability of death.
 386 While been fully vaccinated was associated with improved outcomes (OR: 0.25, 95% CI:
 387 0.12-0.46, $p = 2.89e-05$). Odds ratios and estimates for all variables in the model are
 388 available in Supplementary Table S4. Finally, age was also found to correlate with
 389 mortality (Cox test, $p < 0.001$) in the Kaplan-Meier curves (Fig. 3C), as well as D-dimer
 390 above $1.87 \mu\text{g/mL}$ independently from vaccination or comorbidities (Cox test, $p = 0.02$).



391
 392 **Figure 4. Variables affecting outcome in COVID-19 patients.** A. Forest plot of the two fitted Generalized
 393 Linear Model (GLM) representing the odds ratio and 95% IC for each variable. Estimates are available in
 394 Supplementary Table S4. B. Kaplan-Meier curve depicting the survival probability of patients with different

395 age ranges. C. Kaplan-Meier curve depicting the survival probability of patients with different values for D
396 dimer. All models were constructed using outcome (deceased or recovered) standardized at 28 days. Units:
397 Platelets ($\times 10^9/l$), Lactate dehydrogenase (LDH) (u/L), D dimer (ug/dL), and Blood Urea Nitrogen (BUN)
398 (mg/dL).

399


400 **SARS-CoV-2 lineages: phylogeny, distribution, and its impact on disease severity**

401 We identified the lineages of 386 (38%) samples by partial or complete genome sequencing
402 (Table 3). From this subset of samples, we detected VOC such as Alpha (2.3%), Gamma
403 (7.2%), Delta (68.6%), and Mu (3.6%), originally designated as VOI. We also detected
404 sequences belonging to lineage B.1.1.519 (14.7%) and other lineages (2.86%). The
405 distribution of lineages with a clear dominance of Delta, and in less proportion of B.1.1.519
406 was also observed between March and September 2021 nationwide, as well as in the State
407 of Mexico, and Mexico City (Fig.5A, statistical differences are available in Supplementary
408 Table S5).

409 Furthermore, we also found differences in the distribution of SARS-CoV-2 lineages
410 between outpatients and hospitalized patients (Table 3). In particular, we found the highest
411 proportion of Delta variant in outpatients (82.5%, Chi-square test, $p < 0.001$), while
412 B.1.1.519 represented the highest proportion in hospitalized patients (19%, Chi-square test,
413 $p = 0.001$). Notably, the SARS-CoV-2 variant distribution displayed temporal variations,
414 with B.1.1.519 being more prevalent in March and April 2020, and Delta becoming the
415 predominant lineage in July (Fig. 5C). Furthermore, we found a general increase in the
416 proportion of vaccinated patients during the study period (Fig. 5D). These temporal
417 variations make complex the analysis of potential associations between disease severity and
418 lineages. It is worth mentioning that the number of critical and severe patients (green and

419 purple colors) seems to decrease as the vaccination increases (Fig. 5D). Altogether, we
 420 found no significant association between disease severity and lineages (Supplementary Fig.
 421 S3). Nonetheless, when analyzing the symptoms associated with patients infected with
 422 different lineages, we noted that diarrhea tended to be associated more frequently with
 423 B.1.1.519 infections (Fig. 5B).

424



425

426 **Figure 5. SARS-CoV-2 lineages distribution and its impact on disease severity.** **A.** Distribution of SARS-
 427 CoV-2 lineages at the country level (Mexico), Metropolitan area (the State of Mexico and Mexico City), and
 428 our research center (INER). **B.** Heatmap of the principal symptoms among patients infected with the different
 429 SARS-CoV-2 lineages. **C.** Dominance of lineages in our cohort along time (months). **D.** Distribution of
 430 patients with either mild, severe, or critical COVID-19 classification and percentage of fully vaccinated
 431 patients in our cohort through time (months).

432

433

434

435 **Table 3. SARS-CoV-2 lineages between outpatients and hospitalized patients.**

Lineages	Outpatients (N=123)	Hospitalized (N=263)	P value
Alpha, n (%)	2 (1.5%)	7 (2.6%)	<i>ns</i>
Gamma, n (%)	4 (3.1%)	24 (9.1%)	<i>ns</i>
Delta, n (%)	104 (82.5%)	163 (61.9%)	<0.001
Mu, n (%)	3 (2.3%)	11 (4.1%)	<i>ns</i>
B.1.1.519, n (%)	7 (5.5%)	50 (19%)	0.001
Other, n (%)	3 (2.3%)	8 (3.04%)	<i>ns</i>

436 P values were obtained from Chi-square or Fisher exact test.

437

438 Finally, the phylogenetic analyses based on complete Spike sequences showed, as expected,
439 a specific clustering by lineages, with the Delta variant representing 69% of the samples
440 (Suppl. Figure S4). The sequences of patients with different vaccination statuses or severity
441 classifications did not form specific clusters; suggesting no association between SARS-
442 CoV-2 lineages and vaccination status or COVID-19 severity.

443

444 **DISCUSSION**

445 Vaccines have significantly improved the COVID-19 survival rate around the world, but
446 they are less effective at protecting from SARS-CoV-2 infections, leading to mostly mild
447 infections in vaccinated individuals. Understanding the impact of viral variants, and host
448 factors on disease severity is critical to guide COVID-19 vaccination campaigns and the
449 implementation of protective measures. In this retrospective study, we analyzed the severity
450 of COVID-19 infections in a group of individuals that had been vaccinated with all
451 different types of vaccines applied to the Mexican population. We compared this group
452 with unvaccinated individuals and performed additional analyses, including virological
453 features obtained from genomic surveillance.

454

455

456

457 **Impact of host factors and vaccination status on COVID-19 severity**

458 It is known that host factors such as advanced age and the presence of comorbidities
459 significantly worsen clinical outcomes for COVID-19 patients [28]. The Mexican
460 population is characterized by a high prevalence of comorbidities [29], which is reflected in
461 our cohort, with diabetes (20.5%), hypertension (25.5%), and obesity (39.4%) being the
462 most common. Moreover, it is important to consider that the vaccination campaign in
463 Mexico started at the end of 2020 and first focused on health care workers before moving
464 on to individuals over 60, 50, and 40 years old in February, May, and June, respectively. As
465 a result, in our cohort, the prevalence of comorbidities was even higher in fully vaccinated
466 patients (Table 1), with more than 90% presenting at least one comorbidity, and over 75%
467 were older than 60 years of age. Some studies have shown that the presence of
468 comorbidities and advanced ages can also affect vaccines' effectiveness [12]. Moreover, in
469 both COVID-19 [6,22,30] and Influenza disease [31], it has been shown that advanced age
470 is related to a lower immune response to vaccination. Furthermore, a recent study showed
471 that although vaccinated patients were less likely to present severe disease, vaccinated
472 patients with comorbidities and older age developed severe disease [6]. This is similar to
473 our study where we observed that fully vaccinated patients presented the highest values of
474 severity on the APACHE II scale (Table 2). Nonetheless, when compared to unvaccinated
475 individuals, the vaccinated group showed the lowest mortality rate (Table 2) and required
476 mechanical ventilation less frequently (Fig.1C). These observations confirm that although
477 the vaccine's protective effect may be reduced in individuals with risk factors, they still
478 provide protection against fatal outcomes.

479

480 Moreover, we found that a significant proportion of patients had either severe or critical
481 outcomes, regardless of age and vaccination status (Fig.1A). Although this could be a
482 consequence of studying a cohort of patients in a tertiary hospital limited to the attention of
483 critically ill individuals, it also could be the result of the presence of comorbidities and host
484 genetic factors [32,33]. However, it is essential to highlight that the highest proportion of
485 patients with mild disease was in those fully vaccinated and under 30 years of age (Suppl.
486 Table S1), this evidences the combined protective effect of younger ages and complete
487 vaccination schemes [34].

488 In addition, we analyzed laboratory parameters by vaccination status and age groups.
489 Regardless of the vaccination status, patients older than 61 years exhibited the highest
490 values for BUN, urea, creatinine, and D-dimer (Fig. 2). This is of special relevance since
491 such parameters are known as markers of disease severity and are commonly found
492 elevated in individuals with acute infections [35]. Moreover, urea, BUN, and creatinine are
493 also markers for renal damage and acute kidney injury (AKI), which are conditions that
494 strongly impact mortality [36]. Also, hypoalbuminemia, found in older COVID-19 patients,
495 could be a manifestation of a pro-inflammatory state [37]. Finally, high levels of D-dimer
496 have been found related to mortality in patients with infection or sepsis [38].

497

498 **Impact of different vaccines on the severity of the disease**

499 It is important to point out that this study was not designed to assess vaccine effectiveness
500 against COVID-19. However, Mexico is one of the few countries that used seven different
501 vaccines, offering a unique opportunity to compare these vaccine types and to look for
502 differences in severity and/or mortality. In this study, by analyzing solely patients above 61
503 years old we found, in general, a high proportion of critical patients but low mortality rates

504 regardless of the vaccine applied (Suppl. Table S2). Nonetheless, our findings of lower
505 SOFA index, a higher proportion of patients with mild disease, and higher usage of nasal
506 cannula in patients vaccinated with the Pfizer vaccine may suggest a lower severity of
507 disease in the group that received this vaccine. Some studies have shown that the
508 vaccination efficacy of mRNA vaccines does not decrease in individuals with comorbidities
509 [39]. Still, no causal associations can be made from this finding, and more investigations
510 are needed to confirm if there is a difference in severity associated with the vaccines and
511 what are the factors behind it.

512

513 **SARS-CoV-2 lineages and their impact on disease severity**

514 Understanding the impact of SARS-CoV-2 lineages on disease severity in both
515 unvaccinated and vaccinated individuals is of major importance, especially since such
516 variants could still emerge due to the evolution pressure driven by the population immunity
517 [5,40,41]. As part of our genomic surveillance program, we characterized the circulating
518 SARS-CoV-2 lineages at the time of the study and analyzed the disease severity and
519 clinical presentation associated with infections caused by particular lineages. Alpha and
520 B.1.1.519 were the predominant lineages from March to May 2021, with Delta becoming
521 the most prevalent by July 2021. In addition, other variants such as Gamma and Mu were
522 also detected, mainly between May and July 2021(Fig. 5- 6).

523 Furthermore, we detected a tendency in patients >60 years old infected with either Delta or
524 B.1.1.519 lineages to course a more severe disease (Suppl. Figure S3). Although this
525 finding was not statistically significant in our study, other studies have reported more
526 severe disease in infections associated with these lineages [10,42]. In particular, mutations
527 in the spike (S) protein of the virus which confer a higher affinity of the S1 domain to the

528 angiotensin converter enzyme 2 (ACE2) are one of the main reasons behind the higher
529 pathogenicity of the Delta variant [42].
530 Regarding symptomatology, there were no remarkable differences except for infections
531 with the B.1.1.519 lineage, since patients reported diarrhea more frequently (Fig.5B). This
532 contrasts with other studies where they found that fever, dyspnea, and sore throat were
533 more prevalent in patients infected with Delta [6,43]. However, a previous study found that
534 dyspnea, cyanosis, and particularly diarrhea were the most frequent symptoms in patients
535 infected with the B.1.1.519 lineage in Mexico [10].
536 Moreover, previous studies analyzing large datasets have found differences in disease
537 severity among patients infected with different lineages [44,45]. Nonetheless, studies with
538 small datasets have failed in detecting such differences [46,47]. Altogether, the reduced
539 sample size and the temporal variation of the lineages may be affecting our results and
540 hinder comparative analyses between lineages and vaccination status or disease severity.

541

542 **Clinical factors affecting COVID-19 clinical outcome**

543 We determined the main factors that lead to fatal outcomes in our cohort. According to the
544 fitted Generalized Linear Models (GLM) (Fig. 4), full vaccination was found to be a
545 protective factor against death by COVID-19. On the contrary, platelets $<175 \times 10^9/l$, age
546 above 61 years old, immune disease, D-dimer $> 1.8 \text{ ug/mL}$, and lactate dehydrogenase
547 (LDH) above 600 u/L were found as risk factors. Notably, thrombocytopenia and high
548 levels of LDH have been found associated with severe COVID-19 in other studies [48,49].
549 Furthermore, contrary to other studies [50] we did identify advanced age as a risk factor
550 itself in COVID-19 patients. It is known that the decline of physiologic functions and the
551 immunosenescence associated with increasing age can negatively affect the host response

552 to infectious diseases [6,22,30]. Finally, we hypothesize that complete vaccination may
553 diminish age negative effect since we found that despite that most of the fully vaccinated
554 patients were >61 years old (78%), 83.3% were discharged from the hospital.
555 Our study includes a considerable number of critical and severe patients enrolled, which
556 allowed us to analyze the impact of vaccination, vaccine type, SARS-CoV-2 lineages, and
557 several host factors on mortality and clinical presentation. However, the source is a single
558 referral hospital, and a pandemic wave mostly by the Delta variant, preventing an analysis
559 among vaccination status and lineages.

560

561 **CONCLUSIONS**

562 Comorbidities and advanced ages were the main risk factors, and complete vaccination
563 schemes with different vaccine types (Pfizer, AstraZeneca, Cansino, SinoVac, and Sputnik)
564 were the most significant protective factor against death by COVID-19. Moreover, we did
565 not find strong associations between a particular lineage (Alpha, Gamma, B.1.1.519, and
566 Delta) and disease severity, highlighting the predominant role of host factors such as age,
567 comorbidities, and vaccination status on COVID-19 outcome.

568 Complete vaccination schemes for the whole population, are key to reducing both
569 hospitalization and death. Nevertheless, public health policy should also focus on the
570 control of comorbidities in the long term, which will improve clinical outcomes not only
571 for COVID-19 but also for other current and emerging diseases. Genomic surveillance is
572 essential to identify circulating VOC, which can help to guide the implementation of
573 targeted epidemiological control measures and laboratory characterization for diagnostic
574 and research purposes.

575

576 **Funding**

577 This work was financially supported by Consejo Nacional de Ciencia y Tecnología:
578 CONACYT-FORDECYT 2020, Grant "Caracterización de la diversidad viral y bacteriana"
579 to JAVP and by grant 057 from the "Ministry of Education, Science, Technology and
580 Innovation (SECTEI) of Mexico City" (to CFA) and grant "Genomic surveillance for
581 SARS-CoV-2 variants in Mexico" to CFA) from the AHF Global Public Health Institute at
582 the University of Miami.

583 **Acknowledgments**

584 We thank Eduardo Márquez García from Unidad de Biología Molecular, INER for
585 technical assistance in Illumina sequencing. We also thank all physicians of the ICU for
586 assistance with patient management.

587 **Authors contributions**

588 Conceptualization: PGD, VAT, SAR, RPP, CFA, and JAVP. Methodology: CB, KTD,
589 MMF, MPG, MEJC, FMN, and JAVP. Formal Analysis: AHT, MVR, RSM, and JAVP.
590 Visualization: AHT. Investigation: PGD, MVR, CB, BT, EP, VAT, KTD, MMF, RSM,
591 FJH, EBV, OB, JAMO, and JAVP. Resources: PGD, VAT, SAR, RPP, CFA, and JAVP.
592 Data Curation: AHT. Writing-Original Draft Preparation: AHT, PGD, MVR, CB, VAT,
593 RSM, RPP, CFA, and JAVP. Writing-Review & Editing: All authors. Supervision: CFA,
594 and JAVP. Funding Acquisition: CFA, and JAVP.

595 **Institutional Review Board Statement**

596 This study was reviewed and approved by the Science, Biosecurity, and Bioethics
597 Committee of the Instituto Nacional de Enfermedades Respiratorias (protocol number B-
598 10-20).

599 **Informed Consent Statement**

600 Informed consent was provided according to the Declaration of Helsinki. Written informed
601 consent has been obtained from the patients and/or from their relatives or authorized legal
602 guardians to publish this paper.

603 **Data Availability Statement**

604 The genomic information generated during the current study is available in the GenBank
605 repository, accession numbers: ON158371-ON158443. The clinical datasets used during
606 the current study are available from the corresponding author on reasonable request.

607 **Conflict of Interest**

608 The authors declare that they have no competing interests. The sponsors had no role in the
609 design, execution, interpretation, or writing on the study.

610

611

612

613

614

615

616

617

618

619

620

621

622 REFERENCES

- 623 1. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al.
624 A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N. Engl. J. Med.* **2020**, *382*, 727–
625 733, doi:10.1056/nejmoa2001017.
- 626 2. Organization, W.H. WHO Coronavirus Disease (COVID-19) Dashboard.
- 627 3. Isabel, S.; Graña-Miraglia, L.; Gutierrez, J.M.; Bundalovic-Torma, C.; Groves, H.E.; Isabel, M.R.;
628 Eshaghi, A.R.; Patel, S.N.; Gubbay, J.B.; Poutanen, T.; et al. Evolutionary and Structural Analyses of
629 SARS-CoV-2 D614G Spike Protein Mutation Now Documented Worldwide. *Sci. Rep.* **2020**, *10*, 1–9,
630 doi:10.1038/s41598-020-70827-z.
- 631 4. Giovanetti, M.; Benedetti, F.; Campisi, G.; Ciccozzi, A.; Fabris, S.; Ceccarelli, G.; Tambone, V.;
632 Caruso, A.; Angeletti, S.; Zella, D.; et al. Evolution Patterns of SARS-CoV-2: Snapshot on Its
633 Genome Variants. *Biochem. Biophys. Res. Commun.* **2021**, *538*, 88–91,
634 doi:10.1016/j.bbrc.2020.10.102.
- 635 5. Harvey, W.T.; Carabelli, A.M.; Jackson, B.; Gupta, R.K.; Thomson, E.C.; Harrison, E.M.; Ludden,
636 C.; Reeve, R.; Rambaut, A.; Peacock, S.J.; et al. SARS-CoV-2 Variants, Spike Mutations and
637 Immune Escape. *Nat. Rev. Microbiol.* **2021**, *19*, 409–424, doi:10.1038/s41579-021-00573-0.
- 638 6. Ong, S.W.; Chiew, C.J.; Ang, L.W.; Mak, T.-M.; Cui, L.; HS Toh, M.P.; Lim, Y.D.; Lee, P.H.; Lee,
639 T.H.; Chia, P.Y.; et al. Clinical and Virological Features of SARS-CoV-2 Variants of Concern: A
640 Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). *Clin.*
641 *Infect. Dis.* **2021**, *August*, 23:ciab721.
- 642 7. Taboada, B.; Zárate, S.; Iña, P.; Boukadida, C.; Vazquez-perez, J.A.; Muñoz-medina, J.E.;
643 Ramírez-gonzález, J.E.; Comas-garcía, A.; Grajales-muñiz, C.; Rincón-rubio, A.; et al. Genetic
644 Analysis of sars-cov-2 Variants in Mexico during the First Year of the covid-19 Pandemic. *Viruses*
645 **2021**, *13*, 1–20, doi:10.3390/v13112161.
- 646 8. Cedro-tanda, A.; Laura, G.; Anda-jauregui, G. De; Garnica-l, D.; Alfaro-mora, Y.; Sonia, S.; Garc,
647 E.F.; Mendoza-vargas, A.; Fr, E.J.; Moreno, B.; et al. Early Genomic, Epidemiological, and Clinical
648 Description of the SARS-CoV-2 Omicron Variant in Mexico City. *Viruses* **2022**, *14*, v14030545.
- 649 9. Rodríguez-Maldonado, A.P.; Vázquez-Pérez, J.A.; Cedro-Tanda, A.; Taboada, B.; Boukadida, C.;

- 650 Wong-Arámula, C.; Nuñez-García, T.E.; Cruz-Ortiz, N.; Barrera-Badillo, G.; Hernández-Rivas, L.;
651 et al. Emergence and Spread of the Potential Variant of Interest (VOI) B.1.1.519 of SARS-CoV-2
652 Predominantly Present in Mexico. *Arch. Virol.* **2021**, *166*, 3173–3177, doi:10.1007/s00705-021-
653 05208-6.
- 654 10. Cedro-tanda, A.; Laura, G.; Anda-jauregui, G. De; Peñaloza, F.; Moreno, B.; Escobar-arrazola, M.A.;
655 Ramirez-vega, O.A.; Munguia-garza, P.; Garcia-cardenas, F.; Cisneros-villanueva, M.; et al. The
656 Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City.
657 *Viruses* **2021**, *13*, v13112182.
- 658 11. Salud, S. de *COVID-19 MÉXICO: Comunicado Técnico Diario*; Mexico City, 2021;
- 659 12. Butt, A.A.; Nafady-hego, H.; Chemaitelly, H.; Abou-Samra, A.-B.; Al Khal, A.; Coyle, P. V.; Al
660 Kanaani, Z.; Kaleeckal, A.H.; Latif, A.N.; Masalmani, Y. Al; et al. Outcomes Among Patients with
661 Breakthrough SARS-CoV-2 Infection After Vaccination. *Int. J. Infect. Dis.* **2020**, *110*, 353–358.
- 662 13. Huang, Y.Z.; Kuan, C.C. Vaccination to Reduce Severe COVID-19 and Mortality in COVID-19
663 Patients: A Systematic Review and Meta-Analysis. *Eur. Rev. Med. Pharmacol. Sci.* **2022**, *26*, 1770–
664 1776, doi:10.26355/eurrev_202203_28248.
- 665 14. Prévost, J.; Finzi, A. The Great Escape? SARS-CoV-2 Variants Evading Neutralizing Responses. *Cell*
666 *Host Microbe* **2021**, *29*, 322–324, doi:10.1016/j.chom.2021.02.010.
- 667 15. Thakur, S.; Sasi, S.; Pillai, S.G.; Nag, A.; Shukla, D.; Singhal, R.; Phalke, S.; Velu, G.S.K. SARS-
668 CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. *Front. Med.* **2022**, *9*,
669 doi:10.3389/fmed.2022.815389.
- 670 16. Bakhshandeh, B.; Jahanafrooz, Z.; Abbasi, A.; Babaee, M.; Sadeghi, M.; Sadeq, M.M.; Zamani, M.
671 Mutations in SARS-CoV-2; Consequences in Structure, Function, and Pathogenicity of the Virus.
672 *Microb. Pathog.* **2020**, *154*, 104831, doi:10.1016/j.micpath.2021.104831.
- 673 17. Bian, L.; Gao, F.; Zhang, J.; He, Q.; Mao, Q.; Xu, M.; Liang, Z. Effects of SARS-CoV-2 Variants on
674 Vaccine Efficacy and Response Strategies. *Expert Rev. Vaccines* **2021**, *20*, 365–373,
675 doi:10.1080/14760584.2021.1903879.
- 676 18. Castillo, A.E.; Parra, B.; Tapia, P.; Acevedo, A.; Lagos, J.; Andrade, W.; Arata, L.; Leal, G.; Barra,
677 G.; Tambley, C.; et al. Phylogenetic Analysis of the First Four SARS-CoV-2 Cases in Chile. *J. Med.*

- 678 *Virol.* **2020**, 92, 1562–1566, doi:10.1002/jmv.25797.
- 679 19. Kumar, S.; Stecher, G.; Li, M.; Knyaz, C.; Tamura, K. MEGA X: Molecular Evolutionary Genetics
680 Analysis across Computing Platforms. *Mol. Biol. Evol.* **2018**, 35, 1547–1549,
681 doi:10.1093/molbev/msy096.
- 682 20. Katoh, K.; Misawa, K.; Kuma, K.I.; Miyata, T. MAFFT: A Novel Method for Rapid Multiple
683 Sequence Alignment Based on Fast Fourier Transform. *Nucleic Acids Res.* **2002**, 30, 3059–3066,
684 doi:10.1093/nar/gkf436.
- 685 21. Rambaut, A. FigTree 2012, 1–8.
- 686 22. Wang, J.; Tong, Y.; Li, D.; Li, J.; Li, Y. The Impact of Age Difference on the Efficacy and Safety of
687 COVID-19 Vaccines: A Systematic Review and Meta-Analysis. *Front. Immunol.* **2021**, 12, 1–8,
688 doi:10.3389/fimmu.2021.758294.
- 689 23. National Institutes of Health *Treatment Guidelines. Coronavirus Disease 2019 (COVID-19)*; 2021;
- 690 24. Team, R.C. R: A Language and Environment for Statistical Computing. 2020.
- 691 25. Wickham, H.; Chang, W.; Pedersen Lin, T.; Takahashi, K.; Wilke, C.; Woo, K. *ggplot2: Elegant*
692 *Graphics for Data Analysis*; Springer-Verlag: New York, 2016; ISBN 978-3-319-24277-4.
- 693 26. Therneau, P.M. A Package for Survival Analysis in R 2020.
- 694 27. Kassambara, A.; Kosinski, M.; Biecek, P. *Survminer: Drawing Survival Curves Using ggplot2* 2021.
- 695 28. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.;
696 Evans, D.; Cockburn, J.; McDonald, H.I.; et al. OpenSAFELY: Factors Associated with COVID-19
697 Death in 17 Million Patients. *Nature* **2020**, 584, 430–436, doi:10.1038/s41586-020-2521-
698 4.OpenSAFELY.
- 699 29. Martos-Benítez, F.D.; Soler-Morejón, C.D.; García-del Barco, D. Chronic Comorbidities and Clinical
700 Outcomes in Patients with and without COVID-19: A Large Population-Based Study Using National
701 Administrative Healthcare Open Data of Mexico. *Intern. Emerg. Med.* **2021**, 16, 1507–1517,
702 doi:10.1007/s11739-020-02597-5.
- 703 30. Collier, D.A.; Ferreira, I.A.T.M.; Kotagiri, P.; Datir, R.P.; Lim, E.Y.; Touizer, E.; Meng, B.;
704 Abdullahi, A.; Baker, S.; Dougan, G.; et al. Age-Related Immune Response Heterogeneity to SARS-
705 CoV-2 Vaccine BNT162b2. *Nature* **2021**, 596, 417–422, doi:10.1038/s41586-021-03739-1.

- 706 31. Gutiérrez-González, E.; Cantero-Escribano, J.M.; Redondo-Bravo, L.; San Juan-Sanz, I.; Robustillo-
707 Rodela, A.; Cendejas-Bueno, E.; Influenza Working Group Effect of Vaccination, Comorbidities and
708 Age on Mortality and Severe Disease Associated with Influenza during the Season 2016–2017 in a
709 Spanish Tertiary Hospital. *J. Infect. Public Health* **2019**, *12*, 486–491,
710 doi:10.1016/j.jiph.2018.11.011.
- 711 32. Asano, T.; Immunol, S.; Asano, T.; Boisson, B.; Onodi, F.; Matuozzo, D.; Moncada-velez, M.; Raj,
712 M.; Maglorius, L.; Zhang, P.; et al. X-Linked Recessive TLR7 Deficiency in ~ 1 % of Men under 60
713 Years Old with Life-Threatening COVID-19. *Sci. Immunol.* **2021**, *4348*, 1–31.
- 714 33. Zeberg, H. The Major Genetic Risk Factor for Severe COVID-19 Is Associated with Protection
715 against HIV. *Proc. Natl. Acad. Sci. U. S. A.* **2022**, *119*, 17–19, doi:10.1073/pnas.2116435119.
- 716 34. Kahn, F.; Bonander, C.; Moghaddassi, M.; Rasmussen, M.; Malmqvist, U.; Inghammar, M.; Björk, J.
717 Risk of Severe COVID-19 from the Delta and Omicron Variants in Relation to Vaccination Status,
718 Sex, Age and Comorbidities - Surveillance Results from Southern Sweden. *medRxiv* **2022**, *27*,
719 doi:10.2807/1560-7917.ES.2022.27.9.2200121.
- 720 35. Markanday, A. Acute Phase Reactants in Infections: Evidence-Based Review and a Guide for
721 Clinician. *Open Forum Infect. Dis.* **2015**, *2*, doi:10.1093/o.
- 722 36. Ng, J.H.; Bijol, V.; Sparks, M.A.; Sise, M.E.; Izzedine, H.; Jhaveri, K.D. Pathophysiology and
723 Pathology of Acute Kidney Injury in Patients With COVID-19. *Adv. Chronic Kidney Dis.* **2020**, *27*,
724 365–376, doi:10.1053/j.ackd.2020.09.003.
- 725 37. Wu, M.A.; Fossali, T.; Pandolfi, L.; Carsana, L.; Ottolina, D.; Frangipane, V.; Rech, R.; Tosoni, A.;
726 Lopez, G.; Agarossi, A.; et al. Hypoalbuminemia in COVID-19: Assessing the Hypothesis for
727 Underlying Pulmonary Capillary Leakage. *J. Intern. Med.* **2021**, *289*, 861–872,
728 doi:10.1111/joim.13208.
- 729 38. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al.
730 Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China:
731 A Retrospective Cohort Study. *Lancet* **2020**, *395*, 1054–1062, doi:10.1016/S0140-6736(20)30566-3.
- 732 39. Choi, W.S.; Cheong, H.J. COVID-19 Vaccination for People with Comorbidities. *Infect. Chemother.*
733 **2021**, *53*, 155–158, doi:10.3947/IC.2021.0302.

- 734 40. Ahmad, L. Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine
735 Breakthrough Infections. *Front. Immunol.* **2021**, *12*, 1–7, doi:10.3389/fimmu.2021.742167.
- 736 41. Lou, F.; Li, M.; Pang, Z.; Jiang, L.; Guan, L.; Tian, L.; Hu, J.; Fan, J.; Fan, H. Understanding the
737 Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. *Front. Immunol.* **2021**, *12*,
738 1–19, doi:10.3389/fimmu.2021.744242.
- 739 42. Moghaddar, M.; Radman, R.; Macreadie, I. Severity, Pathogenicity and Transmissibility of Delta and
740 Lambda Variants of SARS-CoV-2, Toxicity of Spike Protein and Possibilities for Future Prevention
741 of COVID-19. *Microorganisms* **2021**, *9*, doi:10.3390/microorganisms9102167.
- 742 43. Hu, Z.; Huang, X.; Zhang, J.; Fu, S.; Ding, D.; Tao, Z. Differences in Clinical Characteristics
743 Between Delta Variant and Wild-Type SARS-CoV-2 Infected Patients. *Front. Med.* **2022**, *8*, 1–9,
744 doi:10.3389/fmed.2021.792135.
- 745 44. Paredes, M.I.; Lunn, S.M.; Famulare, M.; Frisbie, L.A.; Painter, I.; Burstein, R.; Roychoudhury, P.;
746 Xie, H.; Bakash, S.A.M.; Perez, R.; et al. Associations between SARS-CoV-2 Variants and Risk of
747 COVID-19 Hospitalization among Confirmed Cases in Washington State: A Retrospective Cohort
748 Study. *Clin. Infect. Dis.* **2000**, *12*, 1–18.
- 749 45. Lauring, A.S.; Tenforde, M.W.; Chappell, J.D.; Gaglani, M.; Ginde, A.A.; Mcneal, T.; Ghamande, S.;
750 Douin, D.J.; Talbot, H.K.; Casey, J.D.; et al. Clinical Severity Of, and Effectiveness of mRNA
751 Vaccines Against, Covid-19 from Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United
752 States: Prospective Observational Study. *BMJ* **2022**, *376*, doi:10.1136/bmj-2021-069761.
- 753 46. Everett, J.; Hokama, P.; Roche, A.M.; Reddy, S.; Hwang, Y.; Kessler, L.; Glascock, A.; Li, Y.;
754 Whelan, J.N.; Weiss, S.R.; et al. SARS-CoV-2 Genomic Variation in Space and Time in Hospitalized
755 Patients in Philadelphia. *MBio* **2021**, *12*, 1–16, doi:10.1128/mBio.03456-20.
- 756 47. Boukadida, C.; Taboada, B.; Escalera-Zamudio, M.; Isa, P.; Ramírez-González, J.E.; Vazquez-Perez,
757 J.A.; Muñoz-Medina, J.E.; Grajales-Muñiz, C.; González-Torres, C.; Gaytán-Cervantes, F.J.; et al.
758 Genomic Characterization of SARS-CoV-2 Isolated from Patients with Distinct Disease Outcomes in
759 Mexico. *Microbiol. Spectr.* **2022**, *10*, doi:10.1128/spectrum.01249-21.
- 760 48. Lippi, G.; Plebani, M.; Henry, B.M. Thrombocytopenia Is Associated with Severe Coronavirus
761 Disease 2019 (COVID-19) Infections: A Meta-Analysis. *Clin. Chim. Acta* **2020**, *506*, 145–148,

762 doi:10.1016/j.cca.2020.03.022.

763 49. Henry, B.M.; Aggarwal, G.; Wong, J.; Benoit, S.; Vikse, J.; Plebani, M.; Lippi, G. Lactate
764 Dehydrogenase Levels Predict Coronavirus Disease 2019 (COVID-19) Severity and Mortality: A
765 Pooled Analysis. *Am. J. Emerg. Med.* **2020**, *38*, 1722–1726.

766 50. Stupica, D.; Collinet-Adler, S.; Kejžar, N.; Jagodic, Z.; Poljak, M.; Klevišar, M.N. The Impact of
767 SARS-CoV-2 Primary Vaccination in a Cohort of Patients Hospitalized for Acute COVID-19 during
768 Delta Variant Predominance. *J. Clin. Med.* **2022**, *11*, doi:10.3390/jcm11051191.

769

770

771

772

773

774

775

776

777

778